Skip to main content
. 2011 Jan;6(1):167–174. doi: 10.2215/CJN.06270710

Table 1.

Demographics and clinical characteristics of the patients by MRSA carriage

Characteristic MRSA Noncarrier (n = 277) MRSA Carrier (n = 29) Pa
Age (years) 60.07 (11.88) 60.97 (14.48) 0.7
Gender, men (%) 130 (46.93) 17 (58.62) 0.2
Marriage (%) 0.4
    couple 246 (88.81) 24 (82.76)
    single 31 (11.19) 5 (17.24)
Time on dialysis (months) 126.13 (120.75) 153.90 (147.12) 0.2
Cause of ESRD (%) 0.3
    glomerulonephritis 84 (30.32) 11 (37.93)
    diabetes 121 (43.6) 9 (31.03)
    hypertension 31 (11.19) 2 (6.9)
    other 41 (14.8) 7 (24.14)
Vascular access (%) 0.9
    fistula 192 (69.31) 20 (68.97)
    graft 69 (24.91) 7 (24.14)
    catheter 16 (5.78) 2 (6.9)
Diabetes (%) 147 (53.07) 11 (37.93) 0.1
Hypertension (%) 216 (77.98) 23 (79.31) 0.9
Coronary artery disease (%) 34 (12.27) 4 (13.79) 0.8
Malignancy (%) 11 (3.97) 3 (10.34) 0.1
Karnofsky performance scale 75.70 (18.37) 71.03 (20.41) 0.2
Concurrent active infection (%)b 1 (3.45) 4 (1.44) 0.4
Recent hospitalization (%)c 28 (10.11) 6 (20.69) 0.09
Recent antibiotics use (%)d 49 (17.69) 7 (24.14) 0.4
Albumin (g/dl) 4.06 (0.42) 3.84 (0.61) 0.01
Serum creatinine (mg/dl) 10.4 (2.27) 10.14 (2.32) 0.6
Total cholesterol (mg/dl) 175.46 (43.93) 163.9 (46.53) 0.2
Triglyceride (mg/dl) 173.7 (142.57) 206.86 (246) 0.3
Hemoglobin (g/dl) 10.93 (1.58) 10.55 (2.1) 0.2
WBC count (1000 cells/mm3) 7.45 (2.58) 7.27 (2.39) 0.7
hsCRP (mg/dl) 0.99 (2.08) 1.51 (1.75) 0.2
Single pool Kt/Ve 1.56 (0.27) 1.50 (0.18) 0.2
Follow-up duration (days) 613 (598, 639) 612 (406.5, 639) 0.2
Censored (%)f 28 (10.1) 1 (3.4) 0.3

The data are presented as the means (standard deviation) or number (%). Follow-up duration is presented as median (25th/75th percentile). WBC, white blood cell; hsCRP, high-sensitivity C-reactive protein.

a

The values represent comparisons between the MRSA noncarrier and MRSA carrier groups. Two-sample t tests were used for the comparison of continuous variables other than follow-up duration. χ2 tests or Fisher's exact tests were used for comparison of categorical variables. The Wilcoxon rank sum test was used for comparison of follow-up duration.

b

Defined as having clinical infection at study entry.

c

Defined as hospitalization ≦3 months before study entry.

d

Defined as any antibiotic use ≦3 months before study entry.

e

Calculated using the Daugirdas formula.

f

Censored because of receiving kidney transplantation (n = 5, all were MRSA noncarriers) or transferral to other hemodialysis centers before December 31, 2008.